ACTC and BIOTIME have many crossovers, here is just a few.
October 5, 2007
Michael West steps down as the President and Chief Scientific Officer of ACTC
October 6th, 2007
ACTC retains West as consultant and stays on ACTC BOD's until
year end.
October 10, 2007
BioTime, Inc. named Michael D. West Chief Executive Officer. Dr. West, who has served on the BioTime Board of Directors since 2002,
October 11, 2007
Biotime
ENTRY INTO STEM CELL RESEARCH
AND REGENERATIVE MEDICINE
October 23, 2007
Robert W. Peabody, CPA,
Prior to joining BioTime, Mr. Peabody served as Vice President-Grant Administration for Advanced Cell Technology, Inc (ACT) and also served on their Board of Directors from 1998 to 2006. Mr. Peabody will oversee the operating departments of BioTime as well as assist in applying for research grants to finance the research and development of stem cell and blood volume replacement products.
December 12, 2007 -- BioTime, Inc. (OTCBB:BTIM) today announced that it has organized a new subsidiary, Embryome Sciences, Inc. The mission of the new company is to participate in the emerging field of regenerative medicine known as “embryomics”.
On July 10, 2008
our subsidiary Embryome Sciences, Inc. entered into a License Agreement with Advanced Cell Technology, Inc. (“ACT”) under which Embryome Sciences acquired exclusive world-wide rights to use ACT’s “ACTCellerate” technology for methods to accelerate the isolation of novel cell strains from pluripotent stem cells. The licensed rights include pending patent applications, know-how, and existing cells and cell lines developed using the technology.
